News
CRBU
1.785
+0.85%
0.015
Caribou Biosciences CEO joins H.C. Wainwright cell therapy conference fireside chat
PUBT · 1d ago
Weekly Report: what happened at CRBU last week (0622-0626)?
Weekly Report · 1d ago
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Barchart · 1d ago
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Seeking Alpha · 4d ago
Weekly Report: what happened at CRBU last week (0615-0619)?
Weekly Report · 06/22 10:02
Caribou Biosciences Shareholders Decide Key Governance Matters
TipRanks · 06/18 21:19
Caribou Biosciences shareholders reject officer exculpation charter amendment at annual meeting
PUBT · 06/18 20:03
Analyst Reiterates Buy on Caribou, Citing Strong vispa-cel Data and Pivotal ANTLER-3 Upside; Price Target Maintained at $11
TipRanks · 06/16 10:16
Weekly Report: what happened at CRBU last week (0608-0612)?
Weekly Report · 06/15 10:03
Analyst Reiterates Buy on Caribou Biosciences, Keeps $8 Price Target After Encouraging Allo CAR-T Data
TipRanks · 06/12 00:25
Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained
TipRanks · 06/12 00:19
Caribou Biosciences presents ANTLER trial results at EHA
TipRanks · 06/11 13:03
Caribou Biosciences Highlights Strong Allogeneic CAR-T Trial Results
TipRanks · 06/11 12:38
Caribou Biosciences posts EHA presentation on vispa-cel durability data in B-cell lymphoma trial
PUBT · 06/11 12:18
Caribou Biosciences posts CB-011 CaMMouflage phase 1 follow-up presentation on relapsed/refractory multiple myeloma
PUBT · 06/11 12:17
Caribou says off-the-shelf CAR-T vispa-cel posts 82% response rate in second-line LBCL study
PUBT · 06/11 12:06
Caribou Biosciences Reports Longer Follow Up Data For Ongoing CaMMouflage Phase 1 Trial Of CB-011, Off-The-Shelf BCMA-Targeted CAR-T Cell Therapy, Being Evaluated For r/r MM
Benzinga · 06/11 12:02
Caribou reports durable responses in phase 1 CaMMouflage trial of CB-011 CAR-T in relapsed multiple myeloma
PUBT · 06/11 12:02
Weekly Report: what happened at CRBU last week (0601-0605)?
Weekly Report · 06/08 10:00
Weekly Report: what happened at CRBU last week (0525-0529)?
Weekly Report · 06/01 10:03
More
Webull provides a variety of real-time CRBU stock news. You can receive the latest news about Caribou Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. The Company is dedicated to developing transformative therapies for patients with devastating diseases. The Company's chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy that has been evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy that is being evaluated in patients with relapsed or refractory multiple myeloma.